Opportunity Information: Apply for RFA TR 13 003
Apply for RFA TR 13 003
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Data Management and Coordinating Center (DMCC) for Rare Diseases Clinical Research Network (RDCRN) (U01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.121 Oral Diseases and Disorders Research 93.853 Extramural Research Programs in the Neurosciences and Neurological Disorders.
- This funding opportunity was created on Oct 21, 2013 and posted on Oct 21, 2013.
- Applicants must submit their applications by Dec 19, 2013. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $3,000,000.00 to eligible and selected applicants.
- The number of recipients for this funding is limited to 1 candidate(s).
- Eligible applicants include: For profit organizations other than small businesses Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Independent school districts Private institutions of higher education Public housing authorities/Indian housing authorities Native American tribal organizations (other than Federally recognized tribal governments) State governments Small businesses Special district governments Others (see text field entitled Additional Information on Eligibility for clarification) Native American tribal governments (Federally recognized) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education County governments City or township governments Public and State controlled institutions of higher education.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Asian American Native American Pacific Islander Serving Institutions (AANAPISISs) Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Institutions) are not eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The National Institutes of Health (NIH) announced this discretionary funding opportunity (RFA-TR-13-003) to support a single Data Management and Coordinating Center (DMCC) for the Rare Diseases Clinical Research Network (RDCRN) through a U01 cooperative agreement mechanism. The DMCC is positioned as the central infrastructure hub for the RDCRN, with the overall goal of strengthening and accelerating clinical research across multiple rare diseases by providing coordinated, network-wide operational support, modern clinical data capabilities, and broad access to rare-disease information for both scientific and public audiences. Because this is a cooperative agreement, awardees should expect substantial NIH program involvement in shaping priorities, coordination, and oversight during the project period, rather than a standard grant relationship.
The RDCRN itself is described as a platform for collaborative rare disease clinical research, and the FOA lays out five major network functions that the DMCC is expected to enable. First, it supports collaborative clinical research in rare diseases, including longitudinal studies that follow individuals over time as well as clinical studies and early-stage interventional trials (including phase I, II, and II/III trials). Second, it supports training for clinical investigators who specialize in rare diseases research, reflecting a workforce-development purpose in addition to direct study execution. Third, it supports pilot and demonstration projects that can test feasibility, generate preliminary data, or explore new methods that may later scale to larger studies. Fourth, it emphasizes clinical data management that adopts novel approaches and technologies for data management, data mining, and data sharing across diseases, data types, and technology platforms. Fifth, it highlights access to information related to rare diseases for a wide set of stakeholders, including basic and clinical researchers, academic and practicing physicians, patients, and the general public. The DMCC application is expected to concentrate on innovative ways to provide infrastructure and support to the network sites in carrying out the first three items, while also leading and coordinating the cross-cutting data and information activities described in items four and five.
Functionally, this means the DMCC is expected to act as the backbone for multi-site operations: coordinating study logistics, enabling consistent and high-quality data collection across consortia and projects, and building systems that make it easier to aggregate, analyze, and share data across different rare diseases and study designs. The FOA explicitly points to modernized data strategies, not just traditional database hosting, including approaches that improve interoperability and make network-level data mining and sharing practical across heterogeneous datasets and platforms. Just as importantly, the DMCC is also expected to help make RDCRN outputs and rare-disease knowledge more accessible to non-specialists and patient communities, which typically involves maintaining and curating public-facing information resources and ensuring that research-generated information can be communicated responsibly and clearly.
This FOA is paired with a companion announcement (RFA-TR-13-002), which applicants are directed to consult for the broader network context and related requirements. In terms of award profile, NIH anticipated making one award, with an estimated total funding level of $3,000,000. The opportunity was posted on October 21, 2013, with an original and current closing date of December 19, 2013, and an archive date of January 19, 2014. There is no cost sharing or matching requirement.
Eligibility is broad across U.S.-based organizational types, including for-profit organizations (other than small businesses), small businesses, nonprofit organizations (with or without 501(c)(3) status), public and private institutions of higher education, independent school districts, state, county, and city or township governments, special district governments, public housing authorities/Indian housing authorities, Native American tribal organizations, and federally recognized tribal governments. The eligibility section also explicitly includes a range of mission- or population-serving entities such as HBCUs, Hispanic-serving institutions, tribally controlled colleges and universities, AANAPISIs, Alaska Native and Native Hawaiian serving institutions, faith-based or community-based organizations, regional organizations, U.S. territories or possessions, and eligible federal agencies. Non-U.S. (foreign) institutions and non-U.S. components of U.S. organizations are not eligible to apply, though foreign components as defined by the NIH Grants Policy Statement are allowed, which typically means limited, well-justified foreign elements can be included under an otherwise U.S.-based applicant organization.
The administering agency is the NIH, and the opportunity is categorized under Health, with CFDA numbers 93.121 (Oral Diseases and Disorders Research) and 93.853 (Extramural Research Programs in the Neurosciences and Neurological Disorders). The full announcement was made available through the NIH grants guide at http://grants.nih.gov/grants/guide/rfa-files/RFA-TR-13-003.html, and the provided support contact for access or linking issues is the NIH Office of Extramural Research (OER) webmaster at FBOWebmaster@OD.NIH.GOV.
Frequently Asked Questions (FAQs)
What is this funding opportunity?
This is a National Institutes of Health (NIH) discretionary funding opportunity, RFA-TR-13-003, to support a single Data Management and Coordinating Center (DMCC) for the Rare Diseases Clinical Research Network (RDCRN) using a U01 cooperative agreement mechanism.
What is being funded?
The award supports one DMCC that serves as the central infrastructure hub for the RDCRN, providing coordinated network-wide operational support, modern clinical data capabilities, and broad access to rare-disease information for scientific and public audiences.
How many awards does NIH expect to make?
NIH anticipated making one award.
What is the estimated total funding level for this opportunity?
The estimated total funding level is $3,000,000.
What is the award mechanism and what does it imply?
The mechanism is a U01 cooperative agreement. Because it is a cooperative agreement, awardees should expect substantial NIH program involvement in shaping priorities, coordination, and oversight during the project period, rather than a standard grant relationship.
What is the RDCRN?
The Rare Diseases Clinical Research Network (RDCRN) is described as a platform for collaborative rare disease clinical research.
What are the major RDCRN network functions the DMCC is expected to enable?
The FOA describes five major functions the DMCC is expected to enable across the network:
- Collaborative clinical research in rare diseases, including longitudinal studies, clinical studies, and early-stage interventional trials (including phase I, II, and II/III trials).
- Training for clinical investigators who specialize in rare diseases research.
- Pilot and demonstration projects to test feasibility, generate preliminary data, or explore methods that may later scale to larger studies.
- Clinical data management using novel approaches and technologies for data management, data mining, and data sharing across diseases, data types, and technology platforms.
- Access to information related to rare diseases for stakeholders including researchers, physicians, patients, and the general public.
What should a DMCC application focus on?
The DMCC application is expected to concentrate on innovative ways to provide infrastructure and support to RDCRN network sites in carrying out collaborative clinical research, training, and pilot/demonstration activities, while also leading and coordinating the cross-cutting clinical data management and information-access activities described in the FOA.
What kinds of studies does the RDCRN support (as described in the FOA)?
The FOA describes support for longitudinal studies that follow individuals over time, clinical studies, and early-stage interventional trials, including phase I, II, and II/III trials.
Is workforce development part of the RDCRN mission in this FOA?
Yes. The FOA explicitly includes training for clinical investigators who specialize in rare diseases research.
What are pilot and demonstration projects in this context?
The FOA characterizes pilot and demonstration projects as efforts that can test feasibility, generate preliminary data, or explore new methods that may later scale to larger studies.
What does "modernized data strategies" mean for the DMCC role?
The FOA points to modernized data strategies beyond traditional database hosting, including approaches intended to improve interoperability and make network-level data mining and data sharing practical across heterogeneous datasets and platforms.
What operational role is the DMCC expected to play across sites?
The DMCC is expected to function as the backbone for multi-site operations, coordinating study logistics, enabling consistent and high-quality data collection across consortia and projects, and building systems that support aggregating, analyzing, and sharing data across different rare diseases and study designs.
Who are the intended audiences for RDCRN information access activities?
The FOA emphasizes access to information for a wide range of stakeholders, including basic and clinical researchers, academic and practicing physicians, patients, and the general public.
Does the FOA describe public-facing responsibilities for the DMCC?
Yes. The DMCC is expected to help make RDCRN outputs and rare-disease knowledge more accessible to non-specialists and patient communities, typically involving maintaining and curating public-facing information resources and supporting responsible and clear communication of research-generated information.
Is there a companion funding announcement applicants should review?
Yes. This FOA is paired with a companion announcement, RFA-TR-13-002, which applicants are directed to consult for broader network context and related requirements.
When was the opportunity posted and what are the key dates?
The opportunity was posted on October 21, 2013. The original and current closing date is December 19, 2013. The archive date is January 19, 2014.
Is cost sharing or matching required?
No. There is no cost sharing or matching requirement.
Who is eligible to apply?
Eligibility is broad across U.S.-based organizational types. Examples explicitly included are for-profit organizations (other than small businesses), small businesses, nonprofit organizations (with or without 501(c)(3) status), public and private institutions of higher education, independent school districts, state/county/city or township governments, special district governments, public housing authorities/Indian housing authorities, Native American tribal organizations, and federally recognized tribal governments.
Are minority-serving and community-based organizations included in eligibility?
Yes. The eligibility section explicitly includes entities such as HBCUs, Hispanic-serving institutions, tribally controlled colleges and universities, AANAPISIs, Alaska Native and Native Hawaiian serving institutions, faith-based or community-based organizations, regional organizations, U.S. territories or possessions, and eligible federal agencies.
Are non-U.S. (foreign) organizations eligible to apply?
No. Non-U.S. (foreign) institutions and non-U.S. components of U.S. organizations are not eligible to apply.
Are any foreign components allowed at all?
Yes. Foreign components, as defined by the NIH Grants Policy Statement, are allowed under an otherwise U.S.-based applicant organization, meaning limited and well-justified foreign elements can be included.
Which federal agency administers this opportunity?
The administering agency is the National Institutes of Health (NIH).
How is the opportunity categorized and what CFDA numbers are associated with it?
The opportunity is categorized under Health. The CFDA numbers listed are 93.121 (Oral Diseases and Disorders Research) and 93.853 (Extramural Research Programs in the Neurosciences and Neurological Disorders).
Where can the full announcement be found?
The full announcement is available through the NIH grants guide at http://grants.nih.gov/grants/guide/rfa-files/RFA-TR-13-003.html.
Who should be contacted for access or linking issues with the announcement?
The provided support contact for access or linking issues is the NIH Office of Extramural Research (OER) webmaster at FBOWebmaster@OD.NIH.GOV.
Browse more opportunities from the same category: Health
Next opportunity: Advancing Informal STEM Learning
Previous opportunity: Scholarly Editions and Translations
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA TR 13 003
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA TR 13 003) also looked into and applied for these:
| Funding Opportunity |
|---|
| Basic Research in the Pathogenesis of HIV Related Heart, Lung, and Blood (HLB) Diseases in Adults and Children (R21) Apply for RFA HL 14 029 Funding Number: RFA HL 14 029 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Basic Research in the Pathogenesis of HIV Related Heart, Lung, and Blood (HLB) Diseases in Adults and Children (R01) Apply for RFA HL 14 024 Funding Number: RFA HL 14 024 Agency: National Institutes of Health Category: Health Funding Amount: $499,999 |
| Establishing Outcome Measures for Clinical Studies of Oral and Craniofacial Diseases and Conditions (R21) Apply for PAR 13 380 Funding Number: PAR 13 380 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Establishing Outcome Measures for Clinical Studies of Oral and Craniofacial Diseases and Conditions (R01) Apply for PAR 13 379 Funding Number: PAR 13 379 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Service Area Competition Additional Area (SAC AA) Marquette, Michigan Omaha, Nebraska and Hood River, Oregon Apply for HRSA 14 108 Funding Number: HRSA 14 108 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Secondary Analyses of Social and Behavioral Datasets in Aging (R03) Apply for RFA AG 14 008 Funding Number: RFA AG 14 008 Agency: National Institutes of Health Category: Health Funding Amount: $100,000 |
| Clinical Research in the Prevention, Diagnosis, and Treatment of HIV Related Heart, Lung, and Blood (HLB) Diseases in Adults and Children (R01) Apply for RFA HL 14 023 Funding Number: RFA HL 14 023 Agency: National Institutes of Health Category: Health Funding Amount: $499,999 |
| Pilot Clinical Trials to Eliminate the Latent HIV Reservoir (U01) Apply for RFA AI 13 055 Funding Number: RFA AI 13 055 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| FY14 Region 5 Ohio(Athens, Crawford, DelawareFranklin, Hocking, Lucas, Madison, Mahoning, Marion, Medina, Pickaway, Portage, Richland, Stark, Summit, Trumbull, Union and Wayne counties )Announcement of Anticipated Availability of Funds for Family Apply for PA FPH 14 033 Funding Number: PA FPH 14 033 Agency: Office of the Assistant Secretary for Health Category: Health Funding Amount: $2,924,926 |
| FY14 Region 6 Louisiana(entire state)Announcement of Anticipated Availability of Funds for Family Planning Services Grants Apply for PA FPH 14 034 Funding Number: PA FPH 14 034 Agency: Office of the Assistant Secretary for Health Category: Health Funding Amount: $4,745,826 |
| Reducing Loss to Follow up after Failure to Pass Newborn Hearing Screening Apply for HRSA 14 006 Funding Number: HRSA 14 006 Agency: Health Resources and Services Administration Category: Health Funding Amount: $250,000 |
| Effectiveness of Empiric Antiviral Treatment for Hospitalized Community Acquired Pneumonia during the Influenza Season Apply for RFA IP 14 001 Funding Number: RFA IP 14 001 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $200,000 |
| Affordable Care Act Teaching Health Center Graduate Medical Education (THCGME) Program Apply for HRSA 14 060 Funding Number: HRSA 14 060 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Primary Care Services Resources Coordination and Development Apply for HRSA 14 001 Funding Number: HRSA 14 001 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Blood and Vascular Systems Response to Sepsis (R01) Apply for RFA HL 14 028 Funding Number: RFA HL 14 028 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| STD/HIV Disease Intervention Services Training Centers (DISTC) Apply for CDC RFA PS14 1408 Funding Number: CDC RFA PS14 1408 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $1,000,000 |
| HIV Early Intervention Services (EIS Program) Existing Geographic Service Areas (EISEGA) Apply for HRSA 14 059 Funding Number: HRSA 14 059 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Replication of Key Clinical Trials Initiative (U01) Apply for PAR 13 383 Funding Number: PAR 13 383 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Strengthening the Evidence Base and Capacity for Implementing HIV Prevention and Care and Treatment Programs in the Republic of South Africa under the United States Presidents Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH14 1403 Funding Number: CDC RFA GH14 1403 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $10,000,000 |
| Technical Assistance to Support AIDS Directors and HIV Prevention Program Managers in the 50 States, District of Columbia, the Commonwealth of Puerto Rico, the US Virgin Islands, and the Pacific Islands Apply for CDC RFA PS14 1405 Funding Number: CDC RFA PS14 1405 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $1,000,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA TR 13 003", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.